BMRN BioMarin Pharmaceutical Inc.

83.82
-2.08  -2%
Previous Close 85.9
Open 85.68
Price To Book 5.11
Market Cap 15,009,760,808
Shares 179,071,353
Volume 1,202,342
Short Ratio
Av. Daily Volume 1,459,831

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 interim data released May 28, 2019 - Factor VIII level =36 (23 to 26 weeks).
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 3 top-line data due end of 2019.
Vosoritide
Achondroplasia
Approval announced May 24, 2018.
Palynziq (Pegvaliase)
Phenylketonuria (PKU)
Program terminated June 2016
Reveglucosidase alfa (BMN 701)
Pompe Disease
Approved February 14, 2014.
Vimizim (GALNS)
(MPS IVA) Morquio A Syndrome
PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.
Cerliponase alfa
Batten Disease
CRL issued January 14, 2016.
Kyndrisa
Duchenne Muscular Dystrophy (DMD)
Phase 1/2 three-year data May 28, 2018 noted 96% decrease in bleeding rate. Update regarding regulatory pathway due 3Q 2019.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A
Phase 1/2 dosing has commenced - noted May 15, 2018.
Valoctocogene roxaparvovec (BMN 270)
Hemophilia A with with pre-existing AAV5 antibodies
Phase 2 commencement of dosing announced June 14, 2018.
Vosoritide
Achondroplasia - young children

Latest News

  1. BioMarin Gets $15M From Pfizer on Talzenna's European Nod
  2. Pfizer's Talzenna Gets Approval in Europe for Breast Cancer
  3. BioMarin Earns Milestone Payments from Pfizer for TALZENNA® (talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation
  4. Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up
  5. Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
  6. 9 major Bay Area tech employers pay a typical worker more than $200K per year
  7. 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
  8. Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)
  9. Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?
  10. See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.
  11. 3 Top Growth Stocks to Buy in June
  12. BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
  13. BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA
  14. BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome
  15. 5 Best-Rated Stocks To Buy Amid Selloff
  16. Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?
  17. BioMarin Announces Data on Hemophilia Candidate, Shares Fall
  18. Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion
  19. How BioMarin May Revolutionize the Hemophilia Treatment Market
  20. A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?